On September 25, Gelonghui | Zhigui Health (9955.HK) rose more than 7.8% intraday, reaching a high of 1.24 Hong Kong dollars. In terms of news, recently, Zhigui Health held strategic cooperation talks with the French pharmaceutical company Ipsen, and based on the successful experience of past cooperation, the two sides exchanged views on further expanding cooperation areas and enhancing cooperation effects. Since the cooperation, through resource sharing and complementary advantages, relying on Zhigui Health's strong online and offline reach capabilities and mature operational experience, Ipsen's heavyweight product Dafillin has achieved impressive market performance. Currently, based on two major saas systems inside and outside the hospital, Zhigui Health has built an efficient interconnected ecosystem for more than 2,700 hospitals and nearly 0.23 million pharmacies through deep integration of medical resources. As of the first half of 2024, Zhigui Health has successfully established cooperation relationships with 41 well-known pharmaceutical companies, with the number of cooperation SKUs reaching 50.